Neuland Laboratories is preparing to launch a new commercial peptide manufacturing facility at its 17-acre Bonthapally manufacturing campus, with the first phase expected to become operational in the summer of this year. The project forms part of a broader expansion plan aimed at scaling peptide manufacturing capabilities in response to rising client demand. Once complete, the new facility will operate alongside Neuland’s existing clinical stage S-Block facilities, introducing commercial-scale capacity. The first of four planned modules has already secured firm commitments of approximately USD 30 million, marking a significant step in the company’s entry into large-scale peptide manufacturing.
Module One will deliver a total reactor capacity of 6,370 L across SPPS [solid phase peptide synthesis] and LPPS [liquid phase peptide synthesis] technologies. The LPPS infrastructure will support reactor sizes ranging from 250 L to 3000 L, while SPPS reactors will operate at scales of up to 500 L. Construction began last year and the new infrastructure is designed to support production ranging from small-scale development batches through to multi-ton commercial volumes. The facility has also been designed to accommodate complex and long-chain peptide programs, providing operational flexibility as demand for advanced peptide therapeutics continues to grow.
The company is positioning the new site to support innovator and emerging biotech companies that are encountering tighter access to manufacturing capacity, particularly as GLP-1 manufacturing continues to occupy an increasing share of global peptide production resources. Saharsh Davuluri, Vice Chairman and MD at Neuland Labs, added: “The site has been designed for ongoing expansion, with space to accommodate additional SPPS synthesizers of 2kL and multiple 5kL [LPPS] reactors as future modules come online. This allows us to scale responsibly and in line with customer needs.” Alongside the infrastructure expansion, Neuland plans to significantly increase staffing levels, with R&D headcount expected to grow at a double-digit rate this year while the manufacturing team will more than double to support the production ramp-up. These additions will complement the company’s existing 1,174,000 L of API manufacturing capacity across three US FDA–approved facilities, supported by a large R&D Centre located nearby, enabling efficient scale-up, rapid tech transfer, and streamlined development-to-commercial execution.
“Building on the strength of our reputation among innovator and biotech customers for complex API capabilities, this new facility marks our strategic entry into commercial-scale peptide manufacturing”, added Davuluri. “A key part of our strategy will be to first support innovator and emerging biotech companies across all areas of novel peptide development, as well as the ongoing demand for GLP-1 manufacturing. We see commercial peptide production as a key growth driver for the business over the coming years. So we are now scaling rapidly and expect to rollout all modules of the new peptide facility in line with customer demand.” The development follows a strong period for the CDMO, during which multiple NDAs have recently been filed on behalf of customers, with additional filings anticipated over the next two years. In parallel, Neuland’s LPPS capabilities help ensure reliable supply of peptide building blocks, fragments, intermediates, and hybrid constructs, strengthening supply-chain resilience for complex peptide manufacturing.
The newly completed plants will incorporate advanced digital operational systems controlled through DCS-based automation with eBMR integration, alongside scalable peptide technologies spanning synthesis, purification and drying. Expanded downstream capabilities will include multi-column prep-HPLC systems, commercial-scale lyophilizers and dryers, improved solvent-handling and tank-farm infrastructure, dedicated warehouse facilities, and upgraded waste-management systems designed to support high-volume operations. These systems are intended to enable data-rich process development while helping reduce batch variability and improve manufacturing cycle times.
